Alcobra Ltd. (ADHD) Shares are Down -46.88%

Alcobra Ltd. (ADHD) : During the past 4 weeks, traders have been relatively bearish on Alcobra Ltd. (ADHD), hence the stock is down -47.94% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -46.97% relative to the S&P 500. The 4-week change in the price of the stock is -48.22% and the stock has fallen -46.88% in the past 1 week.

The stock has recorded a 20-day Moving Average of 45.9% and the 50-Day Moving Average is 47.32%.The 200 Day SMA reached 47.83%

Alcobra

Alcobra Ltd. (NASDAQ:ADHD): The stock opened in the green at $2.31 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $2.55 and a low of $2.25 for the day. The stock did not find buyers even at the lows and closed at $2.47 recording a loss of -1.59%. 1,736,853 shares exchanged hands during the trading day. The stock had closed at $2.47 in the previous days trading.

Alcobra Ltd. (ADHD) : Currently there are 6 street experts covering Alcobra Ltd. (ADHD) stock. The most bullish and bearish price target for the stock is $17 and $6 respectively for the short term. The average price target of all the analysts comes to $10.75. The estimated standard deviation from the target is $4.64.

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse. MG01CI product has completed phase two studies.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.